7-[2-[4-(2-methoxyphenyl)piperazinyl]ethyl]-1,3-dimethylxanthine hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-[2-[4-(2-methoxyphenyl)piperazinyl]ethyl]-1,3-dimethylxanthine hydrochloride
• 英文别名: 7-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione;hydrochloride
• 化学式: C₂₀H₂₆N₆O₃*ClH
• 分子量: 434.926
• InChiKey: UGHIAELLDHLWAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7-[2-[4-(2-methoxyphenyl)piperazinyl]ethyl]-1,3-dimethylxanthine hydrochloride 、 sodium Oleate 以 甲醇 、 水 为溶剂， 反应 1.0h， 以16.3 g的产率得到7-[2-[4-(2-methoxyphenyl)piperazinyl]ethyl]-1,3-dimethylxanthine oleate
  参考文献：
  名称：

  [EN] SAA DERIVATIVE COMPOUND RESTORES ENOS AND INHIBITS OXIDATIVE STRESS-INDUCED DISEASES IN HYPOXIA
  [FR] COMPOSÉ DÉRIVÉ DE SAA PERMETTANT LE RÉTABLISSEMENT DE L'ENOS ET INHIBANT LES AFFECTIONS INDUITES PAR LE STRESS OXYDATIF DANS L'HYPOXIE

  摘要：

  所披露的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物被描述为具有抑制由氧化应激引起的疾病的功能的组合物，更特别地是那些能够抑制由氧化应激引起的神经退行性疾病、肺部疾病、氧化应激诱导的心脏疾病和心脏功能障碍的SAA衍生物化合物。

  公开号：

  WO2015161510A1

文献信息

• KMUPS INHIBITING PROLIFERATION AND OBLITERATION OF PULMONARY ARTERY
  申请人：CHEN Ing-Jun

  公开号：US20110201618A1

  公开（公告）日：2011-08-18

  An obstructive pulmonary disease inhibiting pharmaceutical composition is provided. The obstructive pulmonary disease inhibiting pharmaceutical composition includes: an effective amount of a compound of formula I, wherein R 2 and R 4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; and a pharmaceutically acceptable carrier.
• INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL
  申请人：CHEN Ing-Jun

  公开号：US20130095059A1

  公开（公告）日：2013-04-18

  A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight, wherein R 2 and R 4 are each selected independently from a group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group and a halogen atom.
• [EN] SAA DERIVATIVE COMPOUND RESTORES ENOS AND INHIBITS OXIDATIVE STRESS-INDUCED DISEASES IN HYPOXIA<br/>[FR] COMPOSÉ DÉRIVÉ DE SAA PERMETTANT LE RÉTABLISSEMENT DE L'ENOS ET INHIBANT LES AFFECTIONS INDUITES PAR LE STRESS OXYDATIF DANS L'HYPOXIE
  申请人：JANSFAT BIOTECHNOLOGY CO LTD

  公开号：WO2015161510A1

  公开（公告）日：2015-10-29

  The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress consisting of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction.

  所披露的取代胺类似物（SAA）衍生物化合物和SAA复合物化合物被描述为具有抑制由氧化应激引起的疾病的功能的组合物，更特别地是那些能够抑制由氧化应激引起的神经退行性疾病、肺部疾病、氧化应激诱导的心脏疾病和心脏功能障碍的SAA衍生物化合物。